ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Long-Term Outcome After Liver Transplantation for Unresectable Hepatocellular Carcinoma Following Yttrium-90 Radioembolization Bridging Treatment

S. Radunz,1 T. Benkoe,1 J. Best,2 A. Bockisch,3 T. Lauenstein,4 H. Baba,5 A. Paul,1 J. Treckmann.1

1General, Visceral and Transplantation Surgery, University Hospital Essen, Essen, Germany
2Gastroenterology and Hepatology, University Hospital Essen, Essen, Germany
3Nuclear Medicine, University Hospital Essen, Essen, Germany
4Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany
5Pathology and Neuropathology, University Hospital Essen, Essen, Germany.

Meeting: 2015 American Transplant Congress

Abstract number: D190

Keywords: Hepatocellular carcinoma, Liver transplantation, Survival, Tumor recurrence

Session Information

Date: Tuesday, May 5, 2015

Session Name: Poster Session D: Liver Transplantation for Hepatocellular Carcinoma

Session Time: 5:30pm-6:30pm

 Presentation Time: 5:30pm-6:30pm

Location: Exhibit Hall E

Related Abstracts
  • Longitudinal Trends in Wait Times and Use of Bridging Locoregional Therapies in Hepatocellular Carcinoma Patients undergoing Orthotopic Liver Transplantation: UNOS Population Study
  • Effects of Locoregional Treatment and “Downstaging” on Long-Term Post-Liver Transplant Outcomes for Patients with Hepatocellular Carcinoma

Background: Liver transplantation remains the only curative treatment option for patients with unresectable hepatocellular carcinoma (HCC). Several bridging treatments are employed because the limited availability of donor organs prolongs waiting time and increases risk of tumor progression. Purpose of our study was to evaluate our experience with the use of (90)Y radioembolization in maintaining potential candidacy for liver transplantation.

Methods: A retrospective review of 34 consecutive patients with HCC who underwent liver transplantation and had been treated with (90)Y radioembolization as a sole modality for locoregional bridging treatment was performed. Demographics, pathologic response, survival, and tumor recurrence were examined.

Results: (90)Y treatments were performed in 34 patients before transplantation in our center since 2007. Median time from first treatment to transplantation was 4.6 months. HCC in 9 patients met the Milan criteria at the time of the first (90)Y treatment and these patients remained within the criteria before transplantation. Complete necrosis of tumor with no evidence of viable tumor on pathologic examination was observed in 13 patients (38%). Partial necrosis was seen in 16 patients (47%). Seven patients developed recurrent HCC. Median time from liver transplantation to tumor recurrence was 13 months.

Conclusion: Particularly in regions with long wait list times (90)Y bridging treatment is effective in maintaining tumor size and achieving tumor necrosis in potential liver transplantation candidates with HCC.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Radunz S, Benkoe T, Best J, Bockisch A, Lauenstein T, Baba H, Paul A, Treckmann J. Long-Term Outcome After Liver Transplantation for Unresectable Hepatocellular Carcinoma Following Yttrium-90 Radioembolization Bridging Treatment [abstract]. Am J Transplant. 2015; 15 (suppl 3). https://atcmeetingabstracts.com/abstract/long-term-outcome-after-liver-transplantation-for-unresectable-hepatocellular-carcinoma-following-yttrium-90-radioembolization-bridging-treatment/. Accessed January 18, 2021.

« Back to 2015 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Penis Transplantation: First U.S. Experience.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Live Related Kidney Transplant Experience in Abuja, Nigeria – First Eight Cases Ever.
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Penis Transplantation: First U.S. Experience.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.